The quality scheme currently consists of QA rounds for several disease categories (ALL and B-cell lymphoma (FL and MCL)), for different molecular markers (IG/TR gene rearrangements, KMT2A gene rearrangements, BCR::ABL1, IGH::CCND1, and IGH::BCL2 fusion genes), and for different techniques (RQ-PCR, ddPCR, and amplicon NGS) aiming at collaborative standardization of established MRD techniques and evaluation of new MRD strategies. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.